Market Report Focused on 65 kDa PhosphoproteinPP65, Cytomegalovirus-Pipeline Review, H1 2016

65 kDa PhosphoproteinPP65 or Tegument Protein UL83, Cytomegalovirus-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted pipeline therapeutics.

The report provides comprehensive information on the 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics development and features dormant and discontinued projects.

To view the table of contents and know more details please visit 65 kDa PhosphoproteinPP65 or Tegument Protein UL83, Cytomegalovirus-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report reviews key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics and enlists all their major and minor projects 
- The report assesses 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Devise corrective measures for pipeline projects by understanding 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Astellas Pharma Inc. Atara Biotherapeutics, Inc. Immunomic Therapeutics, Inc. Vakzine Projekt Management GmbH Vical Incorporated

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###